CELL INTELLIGENCE · 肿瘤细胞治疗研究

Rab5 通过减少自相残杀并维持表面 CAR 水平改善 CAR-T 细胞疗效

Rab5 improves CAR T cell efficacy via reducing fratricide and maintaining surface CAR levels.

CAR 工程化细胞治疗：当前认识与未来展望

CAR-engineered cell therapies: current understandings and future perspectives.

CAR-T 细胞疗法在实体瘤中的挑战与局限：为何获批仅限于血液系统恶性肿瘤？

Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

使用溶瘤病毒将 T 细胞衔接器重定向以靶向实体瘤的通用即用型联合免疫疗法

Universal off-the-shelf combination immunotherapy using oncolytic viruses to redirect T cell engagers to target solid tumors.

我们的研究结果表明，OV 与 TCEs 的联合提供了一种有前景的策略，可驱动针对实体瘤的抗肿瘤免疫应答。该方法代表了一种新颖且通用的平台，目前正处于将 TCE 疗法与溶瘤病毒疗法联合的 1 期临床试验中，克服了抗原异质性和免疫屏障，从而实现实体瘤的有效治疗。

CAR 疗法在肿瘤与自身免疫领域的演进：机制见解与治疗创新

The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations.

肿瘤 CAR-T 细胞治疗：当前挑战与未来方向

CAR-T cell therapy for cancer: current challenges and future directions.

临床试验中 CAR-T 细胞疗法治疗癌症的治疗相关不良事件：系统综述和荟萃分析

Treatment-related adverse events of chimeric antigen receptor-T therapies for cancers in clinical trials: a systematic review and meta-analysis.

我们的研究提供了与不同 CAR-T 细胞治疗相关不良事件的全面数据，描绘了完整的毒性特征，并为临床医生选择和 manage 抗肿瘤治疗提供了重要参考。

CAR-T 细胞治疗后非 ICANS 神经系统并发症：来自 EBMT 实践协调与指南委员会的建议

Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

描绘细胞治疗格局：中国临床试验与监管进展的洞见

Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China.

揭示 T 细胞耗竭：对 CAR-T 细胞治疗的启示与意义

Unlocking T cell exhaustion: Insights and implications for CAR-T cell therapy.